1. Home
  2. CGEN

CGEN

Compugen Ltd.

Logo Compugen Ltd.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Founded: N/A Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 170.1M IPO Year: 2000
Target Price: $7.25 AVG Volume (30 days): 598.0K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.21 EPS Growth: N/A
52 Week Low/High: $0.53 - $3.03 Next Earning Date: 05-13-2024
Revenue: $33,459,000 Revenue Growth: N/A
Revenue Growth (this year): 17.67% Revenue Growth (next year): -39.05%

Share on Social Networks: